布南色林对早期利培酮治疗无应答首发精神分裂症患者神经因子的影响  

Effect of blonanserin on nerve factors in patients with non-responsive first-episode schizophrenia treated with early risperidone

作　　者：蔡丽丽 黄光彪 钟华[1] 陆梅娟[1] 孙莉 CAI Li-li;HUANG Guang-biao;ZHONG Hua;LU Mei-juan;SUN Li(The Third People's Hospital of Huzhou,Huzhou 313000,China)

机构地区：[1]湖州市第三人民医院精神科,313000

出　　处：《临床精神医学杂志》2024年第4期276-279,共4页Journal of Clinical Psychiatry

基　　金：湖州市公益性应用研究医卫一般项目(2021GYB09)。

摘　　要：目的:探讨布南色林对早期利培酮治疗无应答首发精神分裂症患者神经递质表达的影响。方法:选取本院2022年1月至2022年12月期间住院治疗的120例早期行利培酮单药治疗无应答的首发精神分裂症患者作为研究对象,对照组和研究组各60例。对照组给予氯氮平治疗,研究组给予布南色林治疗,疗程3个月。比较两组患者阳性和阴性精神症状评定量表(positive and negative syndrome scale,PANSS)评分、生活质量综合评定问卷(generic quality of life inventory-74,GQOLI-74)评分、血清脑源性神经营养因子(brain derived neurotrophic factor,BDNF)浓度、血清S100β蛋白、神经元特异性烯醇化酶(neuron specific enolase,NSE)以及神经调节蛋白1(nerve regulatory protein 1,NRG1)水平,记录患者出现的药物不良反应。结果:治疗3个月后,两组PANSS评分均较治疗前有所下降,且研究组PANSS评分更低;两组躯体功能、社会功能、心理功能评分均高于治疗前,且研究组评分高于对照组,差异均有统计学意义(P均<0.05)。治疗3个月后,两组血清BDNF以及NRG1水平高于治疗前,且研究组高于对照组;两组S100β、NSE水平低于治疗前,且研究组低于对照组,差异均有统计学意义(P均<0.05)。两组均未发生严重不良反应事件。结论:布南色林可有效改善早期利培酮单药治疗无应答首发精神分裂症患者的症状,且能够合理调节患者神经递质表达,改善患者认知功能。Objective:To investigate the effect of Blonanserin on the expression of neurotransmitters in patients with non-responding first-episode schizophrenia treated with early risperidone.Method:A total of 120 patients with first-episode schizophrenia who were hospitalized from January 2022 to December 2022 and did not respond to early risperidone monotherapy were selected as the study subjects.There were 60 cases in the control group and 60 cases in the observation group.The control group was treated with olanzapine,and the observation group was treated with Blonanserin.After 3 months of treatment,the positive and negative syndrome scale(PANSS),generic quality of life inventory-74(GQOLI-74)score,serum brain derived neurotrophic factor(BDNF),serum S100βprotein,neuron specific enolase(NSE)and nerve regulatory protein 1(NRG1)levels of the two groups were compared,and the adverse drug reactions of patients were recorded.Results:After 3 months of treatment,PANSS scores in both groups decreased compared with those before treatment,and PANSS scores in the observation group were lower;The scores of physical function,social function and psychological function in the two groups were higher than those before treatment,and the scores in the observation group were higher than those in the control group,with a statistically significant difference(all P<0.05).After 3 months of treatment,the levels of serum BDNF and NRG1 in the two groups were higher than those before treatment,and those in the observation group were higher than those in the control group;Two groups S100β、NSE level in both groups were lower than that before treatment,and that in the observation group was lower than that in the control group;The difference was statistically significant(all P<0.05).No serious adverse reactions occurred in both groups.Conclusion:Blonanserin can effectively improve the symptoms of early risperidone monotherapy in patients with non-responsive first-episode schizophrenia,and can reasonably regulate the expression of neurotransmitters in

关 键 词：精神分裂症 布南色林 脑源性神经营养因子 生活质量 

分 类 号：R749.3[医药卫生—神经病学与精神病学]